Charta Aetatis Cyberpunk

Newsletter Pro Sign in Early access Register
Aa · Display
Themes
Type size
Density
MorningStar Security is in early access. The wiki is open to everyone; the news desks open with a code. Have a code, or want launch notice?
Export
growing · 2 feeds

Lipfendra

First oral PCSK9 inhibitor approved by FDA for reducing LDL cholesterol in adults with hypercholesterolemia

News volume No stories in the last 90 days
23 Aug: 0 stories24 Aug: 0 stories25 Aug: 0 stories26 Aug: 0 stories27 Aug: 0 stories28 Aug: 0 stories29 Aug: 0 stories30 Aug: 0 stories31 Aug: 0 stories1 Sep: 0 stories2 Sep: 0 stories3 Sep: 0 stories4 Sep: 0 stories5 Sep: 0 stories6 Sep: 0 stories7 Sep: 0 stories8 Sep: 0 stories9 Sep: 0 stories10 Sep: 0 stories11 Sep: 0 stories12 Sep: 0 stories13 Sep: 0 stories14 Sep: 0 stories15 Sep: 0 stories16 Sep: 0 stories17 Sep: 0 stories18 Sep: 0 stories19 Sep: 0 stories20 Sep: 0 stories21 Sep: 0 stories22 Sep: 0 stories23 Sep: 0 stories24 Sep: 0 stories25 Sep: 0 stories26 Sep: 0 stories27 Sep: 0 stories28 Sep: 0 stories29 Sep: 0 stories30 Sep: 0 stories1 Oct: 0 stories2 Oct: 0 stories3 Oct: 0 stories4 Oct: 0 stories5 Oct: 0 stories6 Oct: 0 stories7 Oct: 0 stories8 Oct: 0 stories9 Oct: 0 stories10 Oct: 0 stories11 Oct: 0 stories12 Oct: 0 stories13 Oct: 0 stories14 Oct: 0 stories15 Oct: 0 stories16 Oct: 0 stories17 Oct: 0 stories18 Oct: 0 stories19 Oct: 0 stories20 Oct: 0 stories21 Oct: 0 stories22 Oct: 0 stories23 Oct: 0 stories24 Oct: 0 stories25 Oct: 0 stories26 Oct: 0 stories27 Oct: 0 stories28 Oct: 0 stories29 Oct: 0 stories30 Oct: 0 stories31 Oct: 0 stories1 Nov: 0 stories2 Nov: 0 stories3 Nov: 0 stories4 Nov: 0 stories5 Nov: 0 stories6 Nov: 0 stories7 Nov: 0 stories8 Nov: 0 stories9 Nov: 0 stories10 Nov: 0 stories11 Nov: 0 stories12 Nov: 0 stories13 Nov: 0 stories14 Nov: 0 stories15 Nov: 0 stories16 Nov: 0 stories17 Nov: 0 stories18 Nov: 0 stories19 Nov: 0 stories20 Nov: 0 stories
Snapshot
Category
PCSK9 inhibitor 1 source
Intelligence coverage

Lipfendra is an oral PCSK9 inhibitor and the first oral formulation of this drug class 1. Manufactured by Merck 2, it received FDA approval as a once-daily tablet for reducing LDL cholesterol in adults with hypercholesterolemia 2.

Clinical efficacy was demonstrated in two randomized controlled trials enrolling 3,207 adults with hypercholesterolemia 1. In the ASCVD trial, Lipfendra achieved a 56% reduction in LDL-C, while the HeFH trial showed a 59% reduction at Week 24 1. Overall, the drug reduces LDL cholesterol by an average of nearly 60% in patients with hypercholesterolemia 2.

Adverse reactions observed in the HeFH trial included diarrhea and dizziness, which occurred more frequently than in the placebo group 1.

Facts 2

AttributeValueConfidenceSourcesCited
Vendor Merck low 1 2
Category PCSK9 inhibitor low 1 2

Platform 3

oraloral pilloral tablet, once-daily

Neighbourhood

Developed bySuperseded byDeveloped by Merckinjectable PCSK9 inhi…Merck Sharp & Dohme L… Lipfendra

Developed by 2

Superseded by 1

Supersedes 1

Official links

No official links recorded yet.
Work here? Claim this page with a verified company email or DNS record.

Frequently mentioned together 5

Sources 2

  1. FDA approves new kind of cholesterol pill · Hacker News (YC)
  2. Once-daily LDL cholesterol-smashing pill gets FDA approval · New Atlas
That's Cyber for today

Tomorrow's desk, in your inbox by 06:00 UTC. The week's best stories, every Sunday. The month that mattered, on the 1st.

Drawn from the 519 sources the paper read this month. Text and HTML, one-click unsubscribe, free.

How often
Your desks